{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:51:47Z","timestamp":1791183107387,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11382-5","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:33:13Z","timestamp":1762353193000},"page":"7089-7106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of potent DprE1-targeted antitubercular agents: synthesis and evaluation of PBTZ169\/TBA7371-based derivatives"],"prefix":"10.1007","volume":"30","author":[{"given":"Gunjal Amol","family":"Pandurang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Bapurao","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milendra","family":"Turkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalicharan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"11382_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.798465","volume":"9","author":"C Ding","year":"2022","unstructured":"Ding C, Hu M, Shangguan Y, Guo W, Wang S, Feng X et al (2022) Epidemic trends in high tuberculosis burden countries during the last three decades and feasibility of achieving the global targets at the country level. Front Med 9:798465. https:\/\/doi.org\/10.3389\/fmed.2022.798465","journal-title":"Front Med"},{"issue":"6","key":"11382_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.70027","volume":"104","author":"NG Sonawane","year":"2024","unstructured":"Sonawane NG, Thakur A, Pillai AKS, Sharma A, Gunjal AP, Sharma K (2024) Recent cutting-edge designing strategies for Mtb-DHFR inhibitors as antitubercular agents. Chem Biol Drug Des 104(6):e70027. https:\/\/doi.org\/10.1111\/cbdd.70027","journal-title":"Chem Biol Drug Des"},{"issue":"3","key":"11382_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/resp.14887","volume":"30","author":"S Janssen","year":"2025","unstructured":"Janssen S, Murphy M, Upton C, Allwood B, Diacon AH (2025) Tuberculosis: an update for the clinician. Respirology 30(3):196\u2013205. https:\/\/doi.org\/10.1111\/resp.14887","journal-title":"Respirology"},{"issue":"6","key":"11382_CR4","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1183\/09031936.00193413","volume":"43","author":"T Tanimura","year":"2014","unstructured":"Tanimura T, Jaramillo E, Weil D, Raviglione M, L\u00f6nnroth K (2014) Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 43(6):1763\u20131775. https:\/\/doi.org\/10.1183\/09031936.00193413","journal-title":"Eur Respir J"},{"issue":"15","key":"11382_CR5","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1097\/qad.0000000000000802","volume":"29","author":"RK Gupta","year":"2015","unstructured":"Gupta RK, Lucas SB, Fielding KL, Lawn SD (2015) Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 29(15):1987\u20132002. https:\/\/doi.org\/10.1097\/qad.0000000000000802","journal-title":"AIDS"},{"issue":"9","key":"11382_CR6","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/s2213-8587(14)70109-3","volume":"2","author":"K L\u00f6nnroth","year":"2014","unstructured":"L\u00f6nnroth K, Roglic G, Harries AD (2014) Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2(9):730\u2013739. https:\/\/doi.org\/10.1016\/s2213-8587(14)70109-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"11382_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nrd4001","volume":"12","author":"A Zumla","year":"2013","unstructured":"Zumla A, Nahid P, Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12(5):388\u2013404. https:\/\/doi.org\/10.1038\/nrd4001","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"11382_CR8","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1021\/bi0008940","volume":"39","author":"SL Parikh","year":"2000","unstructured":"Parikh SL, Xiao G, Tonge PJ (2000) Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39(26):7645\u20137650. https:\/\/doi.org\/10.1021\/bi0008940","journal-title":"Biochemistry"},{"key":"11382_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129800","volume":"108","author":"UV Mhetre","year":"2024","unstructured":"Mhetre UV, Haval NB, Bondle GM, Rathod SS, Choudhari PB, Kumari J et al (2024) Design, synthesis and molecular docking study of novel triazole\u2013quinazolinone hybrids as antimalarial and antitubercular agents. Bioorg Med Chem Lett 108:129800. https:\/\/doi.org\/10.1016\/j.bmcl.2024.129800","journal-title":"Bioorg Med Chem Lett"},{"key":"11382_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129551","volume":"97","author":"RD Bakale","year":"2024","unstructured":"Bakale RD, Sulakhe SM, Kasare SL, Sathe BP, Rathod SS, Choudhari PB et al (2024) Design, synthesis and antitubercular assessment of 1, 2, 3-triazole incorporated thiazolylcarboxylate derivatives. Bioorg Med Chem Lett 97:129551. https:\/\/doi.org\/10.1016\/j.bmcl.2023.129551","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"11382_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127579","volume":"30","author":"PS Phatak","year":"2020","unstructured":"Phatak PS, Bakale RD, Kulkarni RS, Dhumal ST, Dixit PP, Krishna VS et al (2020) Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents. Bioorg Med Chem Lett 30(22):127579. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127579","journal-title":"Bioorg Med Chem Lett"},{"issue":"5928","key":"11382_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"V Makarov","year":"2009","unstructured":"Makarov V, Manina G, Mikusova K, M\u00f6llmann U, Ryabova O, Saint-Joanis B et al (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324(5928):801\u2013804. https:\/\/doi.org\/10.1126\/science.1171583","journal-title":"Science"},{"issue":"45","key":"11382_CR13","doi-asserted-by":"publisher","first-page":"40659","DOI":"10.1021\/acsomega.2c05307","volume":"7","author":"PSM Amado","year":"2022","unstructured":"Amado PSM, Woodley C, Cristiano MLS, O\u2019Neill PM (2022) Recent advances of DprE1 inhibitors against Mycobacterium tuberculosis: computational analysis of physicochemical and ADMET properties. ACS Omega 7(45):40659\u201340681. https:\/\/doi.org\/10.1021\/acsomega.2c05307","journal-title":"ACS Omega"},{"issue":"5","key":"11382_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s42452-025-06995-2","volume":"7","author":"AV Snehalatha","year":"2025","unstructured":"Snehalatha AV, Kumar NVA (2025) Clinical trial of DprE1 inhibitors: from bench to bedside. Discov Appl Sci 7(5):473. https:\/\/doi.org\/10.1007\/s42452-025-06995-2","journal-title":"Discov Appl Sci"},{"issue":"3","key":"11382_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/emmm.201303575","volume":"6","author":"V Makarov","year":"2014","unstructured":"Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA et al (2014) Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med 6(3):372\u2013383. https:\/\/doi.org\/10.1002\/emmm.201303575","journal-title":"EMBO Mol Med"},{"issue":"11","key":"11382_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00583-21","volume":"65","author":"GT Robertson","year":"2021","unstructured":"Robertson GT, Ramey ME, Massoudi LM, Carter CL, Zimmerman M, Kaya F et al (2021) Comparative analysis of pharmacodynamics in the C3HeB\/FeJ mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832. Antimicrob Agents Chemother 65(11):e0058321. https:\/\/doi.org\/10.1128\/aac.00583-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20133","key":"11382_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0169-409x(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1\u20133):3\u201326. https:\/\/doi.org\/10.1016\/s0169-409x(00)00129-0","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"11382_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1039\/C2CS35348B","volume":"42","author":"DT Manallack","year":"2013","unstructured":"Manallack DT, Prankerd RJ, Yuriev E, Oprea TI, Chalmers DK (2013) The significance of acid\/base properties in drug discovery. Chem Soc Rev 42(2):485\u2013496. https:\/\/doi.org\/10.1039\/C2CS35348B","journal-title":"Chem Soc Rev"},{"issue":"3","key":"11382_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1021\/cb5007163","volume":"10","author":"J Neres","year":"2015","unstructured":"Neres J, Hartkoorn RC, Chiarelli LR, Gadupudi R, Pasca MR, Mori G et al (2015) 2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem Biol 10(3):705\u2013714. https:\/\/doi.org\/10.1021\/cb5007163","journal-title":"ACS Chem Biol"},{"issue":"1","key":"11382_CR20","doi-asserted-by":"publisher","first-page":"29586","DOI":"10.1038\/s41598-025-14734-1","volume":"15","author":"M Shah","year":"2025","unstructured":"Shah M, Patel I, Khona P, Patel H, Yadav MR, Nagani A (2025) Pyrazolopyridine pyrimidone hybrids as potential DprE1 inhibitors, design, synthesis and biological evaluation as antitubercular agents. Sci Rep 15(1):29586. https:\/\/doi.org\/10.1038\/s41598-025-14734-1","journal-title":"Sci Rep"},{"issue":"42","key":"11382_CR21","doi-asserted-by":"publisher","first-page":"13011","DOI":"10.1002\/anie.201707324","volume":"56","author":"R Liu","year":"2017","unstructured":"Liu R, Lyu X, Batt SM, Hsu M-H, Harbut MB, Vilch\u00e8ze C et al (2017) Determinants of the inhibition of DprE1 and CYP2C9 by antitubercular thiophenes. Angew Chem Int Ed 56(42):13011\u201313015. https:\/\/doi.org\/10.1002\/anie.201707324","journal-title":"Angew Chem Int Ed"},{"key":"11382_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00681-18","author":"J Piton","year":"2018","unstructured":"Piton J, Vocat A, Lupien A, Foo CS, Riabova O, Makarov V et al (2018) Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00681-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"11382_CR23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1080\/07391102.2023.2291826","volume":"43","author":"RD Bakale","year":"2025","unstructured":"Bakale RD, Phatak PS, Rathod SS, Choudhari PB, Rekha EM, Sriram D et al (2025) In vitro and in silico exploration of newly synthesized triazolyl- isonicotinohydrazides as potent antitubercular agents. J Biomol Struct Dyn 43(3):1372\u20131391. https:\/\/doi.org\/10.1080\/07391102.2023.2291826","journal-title":"J Biomol Struct Dyn"},{"issue":"19","key":"11382_CR24","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1128\/jb.184.19.5479-5490.2002","volume":"184","author":"RD Fleischmann","year":"2002","unstructured":"Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J et al (2002) Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 184(19):5479\u20135490. https:\/\/doi.org\/10.1128\/jb.184.19.5479-5490.2002","journal-title":"J Bacteriol"},{"issue":"14","key":"11382_CR25","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1128\/jb.00166-10","volume":"192","author":"TR Ioerger","year":"2010","unstructured":"Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S et al (2010) Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 192(14):3645\u20133653. https:\/\/doi.org\/10.1128\/jb.00166-10","journal-title":"J Bacteriol"},{"issue":"9","key":"11382_CR26","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1128\/jcm.38.9.3200-3204.2000","volume":"38","author":"P Bifani","year":"2000","unstructured":"Bifani P, Moghazeh S, Shopsin B, Driscoll J, Ravikovitch A, Kreiswirth BN (2000) Molecular characterization of Mycobacterium tuberculosis<\/i> H37Rv\/Ra variants: distinguishing the mycobacterial laboratory strain. J Clin Microbiol 38(9):3200\u20133204. https:\/\/doi.org\/10.1128\/jcm.38.9.3200-3204.2000","journal-title":"J Clin Microbiol"},{"issue":"11","key":"11382_CR27","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1021\/ol400620a","volume":"15","author":"SD Burley","year":"2013","unstructured":"Burley SD, Lam VV, Lakner FJ, Bergdahl BM, Parker MA (2013) New route to the ergoline skeleton via cyclization of 4-unsubstituted indoles. Org Lett 15(11):2598\u20132600. https:\/\/doi.org\/10.1021\/ol400620a","journal-title":"Org Lett"},{"issue":"1","key":"11382_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2022.2155638","volume":"38","author":"R Chen","year":"2023","unstructured":"Chen R, Wang Z, Sima L, Cheng H, Luo B, Wang J et al (2023) Design, synthesis and evaluation of 2, 6, 8-substituted imidazopyridine derivatives as potent PI3K\u03b1 inhibitors. J Enzyme Inhib Med Chem 38(1):2155638. https:\/\/doi.org\/10.1080\/14756366.2022.2155638","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"11382_CR29","doi-asserted-by":"publisher","first-page":"11315","DOI":"10.1038\/s41598-024-61901-x","volume":"14","author":"S Dash","year":"2024","unstructured":"Dash S, Rathi E, Kumar A, Chawla K, Kini SG (2024) Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches. Sci Rep 14(1):11315. https:\/\/doi.org\/10.1038\/s41598-024-61901-x","journal-title":"Sci Rep"},{"issue":"2","key":"11382_CR30","doi-asserted-by":"publisher","first-page":"1900287","DOI":"10.1002\/ardp.201900287","volume":"353","author":"K Sharma","year":"2020","unstructured":"Sharma K, Neshat N, Sharma S, Giri N, Srivastava A, Almalki F et al (2020) Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques. Arch Pharm 353(2):1900287. https:\/\/doi.org\/10.1002\/ardp.201900287","journal-title":"Arch Pharm"},{"issue":"1","key":"11382_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/697532","volume":"2014","author":"P Karunakar","year":"2014","unstructured":"Karunakar P, Girija CR, Krishnamurthy V, Krishna V, Shivakumar KV (2014) In silico antitubercular activity analysis of benzofuran and naphthofuran derivatives. Tuberc Res Treat 2014(1):697532. https:\/\/doi.org\/10.1155\/2014\/697532","journal-title":"Tuberc Res Treat"},{"issue":"11","key":"11382_CR32","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1039\/c7md00350a","volume":"8","author":"MA Rather","year":"2017","unstructured":"Rather MA, Lone AM, Teli B, Bhat ZS, Singh P, Maqbool M et al (2017) The synthesis, biological evaluation and structure-activity relationship of 2-phenylaminomethylene-cyclohexane-1,3-diones as specific anti-tuberculosis agents. Medchemcomm 8(11):2133\u20132141. https:\/\/doi.org\/10.1039\/c7md00350a","journal-title":"Medchemcomm"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11382-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11382-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11382-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:02:10Z","timestamp":1791180130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11382-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11382"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11382-5","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"19 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}